differences between semaglutide and tirzepatide key differences, weight loss results (2026) Tirzepatide vs Semaglutide: Weight Loss,

Cardiovascular Outcomes This section reviews current evidence regarding GLP-1 RAs effects on MACE, PAD, CAD, HF, blood pressure, and AF, with detailed findings of trials and meta-analyses discussed in Tables 1 and 2 Major Adverse Cardiac Events Among Patients with T2DM Strong evidence supports using GLP-1 RAs to reduce MACE among patients with T2DM and established CVD

Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders

Clinical trials commonly start with 1 mg weekly and gradually increase the dose to higher levels such as 4 mg, 8 mg, or even 12 mg depending on the study protocol

Standard titration protocol This is closest to what the phase 2 clinical trial used